Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / JANX - Janux seeks FDA nod to start trial of cancer drug JANX008

JANX - Janux seeks FDA nod to start trial of cancer drug JANX008

Janux Therapeutics Inc.

  • Janux Therapeutics ( NASDAQ: JANX ) said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking to start a trial of cancer drug JANX008 in humans.
  • The company added that  JANX008 is in development to treat EGFR-expressing solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN).
  • "We are proud to announce today the submission of Janux’s second IND – a critical milestone for our TRACTr platform as we advance our broad pipeline of next generation immunotherapies," said Janux President and CEO David Campbell.

For further details see:

Janux seeks FDA nod to start trial of cancer drug JANX008
Stock Information
Company Name: Janux Therapeutics Inc.
Stock Symbol: JANX
Market: NASDAQ
Website: januxrx.com
Menu
JANX JANX Quote JANX Short JANX News JANX Articles JANX Message Board
Get JANX Alerts

News, Short Squeeze, Breakout and More Instantly...